Side-by-side comparison of AI visibility scores, market position, and capabilities
Emerald Cloud Lab offers a fully remote, cloud-controlled laboratory with 200+ instrument models; ~$15M ARR as of 2025 with labs in the U.S. and expanded facilities in Austin and Pittsburgh.
Emerald Cloud Lab (ECL) is a biotechnology infrastructure company that enables scientists to conduct real wet-lab experiments entirely remotely through a cloud-based interface. Founded as a spin-out of Emerald Therapeutics, ECL operates physical laboratories stocked with over 200 instrument models — including liquid handlers, mass spectrometers, and genomics tools — that researchers control through its unified Command Center software. Scientists can design, execute, and analyze experiments without ever entering a physical lab, democratizing access to advanced instrumentation that would otherwise require millions in capital expenditure.
Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in early 2025.
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has developed the industry-leading molecular modeling suite used by academic researchers, biotech startups, and large pharmaceutical companies to predict molecular properties, optimize lead compounds, and design drugs with greater precision than traditional empirical approaches.\n\nSchrödinger's platform—spanning FEP+ (free energy perturbation), Glide docking, WaterMap, and machine learning-enhanced property prediction—is used by over 1,700 organizations across pharma, biotech, and materials science. In early 2025, the company signed a landmark $150 million upfront collaboration with Novartis for multi-target drug discovery with potential milestones exceeding $2.3 billion. Software revenue grew 54% year-over-year in Q3 2025 as pharmaceutical companies accelerated adoption of computational-first drug discovery. Schrödinger also operates a proprietary drug pipeline, with SGR-1505 (MALT1 inhibitor) in Phase 1 for B-cell malignancies.\n\nSchrödinger occupies a unique hybrid position—part software platform, part drug discovery company—and is a benchmark of the AI/physics-based drug discovery movement. The company is publicly traded (SDGR) and is recognized as an essential tool for the modern small-molecule drug discovery workflow.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.